A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.


Updates from The Motley Fool

Latest updates on BioCryst Pharmaceuticals from Fool.com.
This Week in Biotech

An FDA approval, an untimely clinical hold, and a smackdown in federal appeals court for one giga...

A Biotech's Swelling Valuation

BioCryst shoots up after its hereditary angioedema drug BCX4161 posts positive phase 1 data.

This Week in Biotech: Part 2

A look at the biggest stories this week in biotech and what they mean for investors.

This Week in Biotech

FDA rulings, comments, and earnings reports take center stage this week.



Stock Performance

View Interactive BCRX Charts
Sponsored by

Key Data Points

Primary metrics and data points about BioCryst Pharmaceuticals.
Current Price: $5.77
Prev Close: $6.73
Open: $6.65
Bid: $5.62
Ask: $5.72
Day's Range: $5.50 - $6.67
52wk Range: $2.60 - $9.25
Volume: 7,305,452
Avg Vol 2,240,687
Market Cap: $464M
P/E (ttm): -9.16
EPS (ttm): ($0.63)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about BioCryst Pharmaceuticals.
CAPS Rating 1 out of 5
 
249 Outperform
86 Underperform
CAPS All Stars
 
43 Outperform
36 Underperform

How do you think BioCryst Pharmaceuticals will perform against the market?



You pick for BioCryst Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Jon P. Stonehouse, CEO

100% Approve

Based on 1 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for BioCryst Pharmaceuticals.

A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers